Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 13/20 | 0.44 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.36 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155960 | 0.91 | IL2 (0.48) | IL2STIM1ORAI1ORAI2HCRTR1 | |
| SCHEMBL12155953 | 0.85 | STIM1 (0.41) | IL2STIM1ORAI1SORT1HCRTR1 | |
| SCHEMBL12155974 | 0.84 | RAB9A (0.49) | SORT1 | |
| SCHEMBL12155962 | 0.80 | SMN1; SMN2 (0.38) | HDAC4HDAC6 | |
| SCHEMBL12155981 | 0.80 | IL2 (0.49) | IL2STIM1ORAI1ORAI2 | |
| SCHEMBL12155963 | 0.79 | NPC1 (0.44) | IL2STIM1ORAI1ORAI2SORT1 | |
| SCHEMBL12155964 | 0.77 | STIM1 (0.48) | IL2STIM1ORAI1HCRTR1 | |
| SCHEMBL17244772 | 0.76 | STIM1 (0.59) | IL2STIM1ORAI1ORAI2 | |
| SCHEMBL12241683 | 0.76 | IL2 (0.58) | IL2STIM1ORAI1ORAI2 | |
| SCHEMBL12156184 | 0.74 | IL2 (0.42) | IL2STIM1ORAI1ORAI2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | IL2 3716/4885STIM1 17/4885ORAI1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.